Stablecoin Development (SDEV) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stablecoin Development (SDEV) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 66.8% versus a loss of 67.6%. Over five years, SDEV leads with a -99.9% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($124.9 million vs $103.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDEV | TNXP |
|---|---|---|
| Share price | $1.99 | $7.28 |
| Market cap | $102.99M | $124.86M |
| 1-day change | -28.42% | -3.58% |
| YTD return | -92.94% | -53.39% |
| 1-year return | -66.83% | -67.63% |
| 5-year return | -99.94% | -100.00% |
| EPS (TTM) | $-21.13 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.75 | $23.06 |
| 52-week low | $0.78 | $7.16 |
| Distance from 52-week high | -98.01% | -68.43% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +511.26% |
| Average volume | 11.42M | 537.49K |
| Shares outstanding | 51.75M | 17.15M |
| Employees | 2 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
SDEV vs TNXP FAQ
Which is bigger, Stablecoin Development or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $124.86M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, SDEV or TNXP?
SDEV returned -66.83% over the past 12 months, compared with -67.63% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Stablecoin Development and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.